Litcius/Paper detail

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, H. S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Jane Yuet Ching Hui, Peter Schmid

2020Annals of Oncology62 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAtezolizumabInternal medicinePlaceboPaclitaxelNab-paclitaxelMetastatic breast cancerBreast cancerPhases of clinical researchTriple-negative breast cancerOncologyGastroenterologyUrologyChemotherapyCancerImmunotherapyPembrolizumabPathologyAlternative medicineCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesProstate Cancer Treatment and Research
LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer | Litcius